-
XYD113: Selective GSPT1 Degradation in MYC Cancers
2026-09-08
The reference study identifies XYD113 as a potent molecular glue degrader that selectively removes GSPT1 through a CRBN-dependent ubiquitin–proteasome mechanism. Its activity across MYC-overexpressing cancer models, favorable substrate selectivity, and oral xenograft efficacy support further investigation while leaving important questions about clinical translation and long-term safety.
-
Rosiglitazone Workflows for Adipose Browning
2026-09-07
Build more informative adipocyte and metabolic assays with Rosiglitazone, a tunable PPARγ perturbation rather than a standalone browning marker. This workflow pairs Brl-49653 with genetic SETD7 models, thermogenic readouts, and insulin-response measurements to separate adipogenesis from beige-fat function.
-
JC-1 Mitochondrial Membrane Potential Assay Guide
2026-09-05
Turn mitochondrial depolarization into a practical, ratiometric endpoint for apoptosis studies, drug screening, and mitochondrial function analysis. This workflow shows how to use CCCP controls, optimize staining, and extend findings from a hypoxia-activated cancer therapy study without mistaking ΔΨm loss for complete proof of apoptosis.
-
Dual Recombinase Tracing Finds No Postnatal Neo-Oogenesis
2026-09-05
Xie, Zhou, and Zheng combine Cre-loxP and Dre-rox lineage tracing to test whether postnatal mouse ovarian cells generate new oocytes. Across physiological aging and busulfan-induced ovarian injury, the study detected no labeled growing oocytes or MII eggs, providing strong in vivo evidence against postnatal neo-oogenesis in mice.
-
cgSHAPE-seq Maps SARS-CoV-2 RNA Degrader Binding
2026-09-04
The reference study introduces cgSHAPE-seq, a sequencing-based strategy that identifies where small molecules bind structured RNA, and applies it to the SARS-CoV-2 5′ untranslated region. Mapping a bulged guanosine in the SL5 four-way helix enabled construction of an RNase L-recruiting chimera that reduced viral RNA expression and inhibited live-virus replication in lung epithelial carcinoma cells.
-
Kanamycin Sulfate: Workflows, Selection & Troubleshooting
2026-09-04
Build more reliable bacterial selection workflows with a water-soluble antibiotic suited to plasmid maintenance, resistance profiling, and protein-synthesis assays. This guide also shows how selection-stage quality control can complement newer circular RNA purification strategies without confusing upstream antibiotic use with downstream RNA processing.
-
Rosiglitazone (Brl-49653) in PPARγ Assays
2026-09-03
Rosiglitazone (Brl-49653) provides a practical ligand-based way to interrogate PPARγ activation in adipogenesis, insulin sensitivity modulation, and PPARG variant rescue. This workflow combines transcriptional, protein-stability, mitochondrial, and metabolic readouts to distinguish genuine pathway rescue from nonspecific changes in cell health.
-
AZD6482 Workflows for PI3Kβ Mechanistic Studies
2026-09-02
AZD6482 is a selective PI3Kβ inhibitor for separating platelet, metabolic, and cell-state signaling effects without treating every phenotype as pan-PI3K suppression. This workflow combines formulation guidance, dose-matrix design, RNA-foci readouts, and troubleshooting for exploratory studies inspired by recent DM1 research.
-
D-Luciferin Potassium Salt for BLI Workflows
2026-09-02
D-Luciferin potassium salt supports repeatable firefly luciferase readouts for tumor cell tracking, reporter assays, and ATP-linked measurements. Its water solubility makes it practical for serial in vivo bioluminescence imaging and controlled in vitro assay optimization, including mechanistic hepatocellular carcinoma studies.
-
Sinapine Targets PLCβ3 EF Hands in Cardiovascular Disease
2026-09-02
The April 2024 Phytomedicine study identifies sinapine as a chemical probe that targets the PLCβ3 EF-hand region, including Asn-260, to disrupt Gαq–PLCβ3 signaling in aldosteronism and hypertension models. Its main innovation is a more axis-focused strategy than direct Gαq inhibition, offering a mechanistic framework for developing PLCβ3-directed cardiovascular interventions while clarifying how downstream calcium assays can complement, but not replace, upstream target validation.
-
Vasopressin Analogues: Mechanisms and Research Uses
2026-09-01
Glavaš and colleagues review how vasopressin structure, receptor pharmacology, and peptide engineering have produced analogues with distinct antidiuretic, vasoconstrictive, and clinical profiles. The article is especially useful as a framework for interpreting lypressin, desmopressin, and terlipressin in receptor studies, treatment of diabetes insipidus, and emerging antiviral research.
-
Triacetin, HDACs, and Glioblastoma Cell Death
2026-08-31
The reference study integrates cell-cycle analysis, HDAC and microRNA expression, mTORC2-related transcripts, and molecular modeling to examine how Triacetin and other acetates affect U87MG glioblastoma cells. Its findings support a mechanistic link between acetate exposure, epigenetic regulation, G2/M arrest, and apoptosis, while remaining limited to an in vitro cancer-cell model.
-
AT13387: A Mechanism-First Cancer Assay Guide
2026-08-31
AT13387 is a high-affinity Hsp90 inhibitor for dissecting oncogenic signaling, cell cycle arrest, and apoptosis induction. This guide connects its cancer biology research applications with a norovirus study that clarifies how selective protein release can be distinguished from nonspecific membrane rupture.
-
Metoprolol Tartrate: Designing β1-Specific Assays
2026-08-30
Metoprolol Tartrate enables selective β1-adrenergic receptor inhibition in cardiovascular research while helping investigators separate cardiac effects from hematopoietic confounders. This guide translates transplant evidence into practical assay-design and interpretation decisions.
-
Oridonin, Inflammation, and Esophageal Cancer
2026-08-29
Peng et al. investigated whether oridonin suppresses esophageal cancer through the TLR4/NF-κB/NLRP3 inflammasome axis in a 4-NQO-induced mouse model. The integrated histological, inflammatory, hematological, transcriptional, and protein-level evidence supports an inflammation-centered mechanism, while the preclinical design also defines important limits for translation.